Q3 Earnings Forecast for Arcus Biosciences Issued By Wedbush

Arcus Biosciences, Inc. (NYSE:RCUS) – Wedbush lowered their Q3 2025 earnings per share (EPS) estimates for Arcus Biosciences in a research report issued on Thursday, August 7th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($1.35) per share for the quarter, down from their previous forecast of ($1.13). Wedbush has a “Outperform” rating and a $33.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences’ Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($3.85) EPS, Q1 2026 earnings at ($1.38) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.85) EPS, FY2027 earnings at ($3.66) EPS and FY2028 earnings at ($0.73) EPS.

A number of other research firms have also weighed in on RCUS. Barclays lowered their target price on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a research note on Wednesday, April 23rd. Wells Fargo & Company lowered their target price on Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. The Goldman Sachs Group lowered their target price on Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating for the company in a research note on Thursday, May 8th. Morgan Stanley lowered their target price on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Finally, Wall Street Zen raised Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Arcus Biosciences Trading Up 1.4%

Shares of RCUS stock opened at $9.19 on Monday. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. The business has a 50-day moving average price of $9.15 and a two-hundred day moving average price of $9.38. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $18.98. The firm has a market cap of $977.56 million, a P/E ratio of -2.90 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.03. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The firm had revenue of $160.00 million during the quarter, compared to analyst estimates of $32.86 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share. The company’s revenue was up 310.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in Arcus Biosciences by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,405 shares of the company’s stock valued at $144,000 after purchasing an additional 6,453 shares during the period. Yousif Capital Management LLC grew its holdings in shares of Arcus Biosciences by 18.6% during the 1st quarter. Yousif Capital Management LLC now owns 24,829 shares of the company’s stock worth $195,000 after acquiring an additional 3,893 shares during the period. Gilead Sciences Inc. purchased a new position in shares of Arcus Biosciences during the 4th quarter worth approximately $447,610,000. Norges Bank purchased a new position in shares of Arcus Biosciences during the 4th quarter worth approximately $507,000. Finally, Amalgamated Bank grew its holdings in shares of Arcus Biosciences by 18.4% during the 1st quarter. Amalgamated Bank now owns 18,797 shares of the company’s stock worth $148,000 after acquiring an additional 2,922 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.